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A STUDY OF COMPARISON OF QT DISPERSION IN ACUTE 
MYOCARDIAL INFARCTION BETWEEN EARLY REPERFUSION 
AND LATE REPERFUSION THERAPY 
 
ABSTRACT:  
INTRODUCTION: Coronary artery disease has become a global pandemic and 
one of the leading causes of morbidity and mortality among non communicable 
diseases. The complications leading to death in acute myocardial infarction such 
as malignant ventricular arrhythmias  are very much preventable. QT dispersion 
(maximum QT interval minus minimum QT interval) was proposed as an index 
of the spatial dispersion of ventricular recovery. QTd measurement is an attempt 
by which we can distinguish homogenous myocardium from inhomogenous 
myocardium. Hence QT dispersion provides a cheap, simple and non invasive 
method to measure underlying dispersion of ventricular excitability. 
MATERIALS AMD METHODS : This is an observational study conducted in 
Government Kilpauk medical college hospital, Department of medicine for a 
period of 1 year. A total of 30 early thrombolysed cases and 30 late 
thrombolysed cases were recruited for the study. QT dispersion was studied 
before thrombolysis, after thrombolysis , 2nd day , 5th day and 6th week post 
thrombolysis in both groups and later compared between both groups. Similarly 
QTd was compared between treatment successful and failed cases. The obtained 
data was tabulated, statistical analysis done and co-relation was studied. 
RESULTS AND CONCLUSION: 
1. QTd was higher among those who were thrombolysed late as compared to 
early group. 
2. QTd was lower in those with successful thrombolysis. 
3. Incidence of arrythmias was high among late group than early indicating 
early successful thrombolysis reduces the occurrence of arrythmias. 
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INTRODUTION 
 
Coronary artery disease has become a global pandemic and one of the 
leading causes of morbidity and mortality among non communicable 
diseases. Most of the STEMI occurs due to sudden occlusion of the 
epicardial coronary artery by a dynamic occlusion by thrombus or critical 
ischemia in a pre-existing diseased coronary artery. The disease burden is 
going to increase in future thence cardiac deaths due to AMI. 
 
The early 30 day mortality rate due to AMI is upto 30% with most of 
the deaths occurring in first 24 hrs particularly in first hour after MI before 
reaching hospital. Most of these deaths are increasingly occurring among 
the young during the productive period of life 
(1)
. 
 
The complications leading to death in acute myocardial infarction 
such as malignant ventricular arrhythmias (like ventricular tachycardia and 
ventricular fibrillation) are very much preventable 
(2)
. 
 
Despite the sobering statistics in the occurrence of AMI and its 
complications there is a decline in the deaths in the early hours after MI due 
to the good treatment. 
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The use of sophisticated battery of tests, like continuous Holter 
Monitoring, Microvolt T wave alternans, Domain ventricular late potentials 
are not available to most of the people 
(3)
. 
 
QT dispersion (maximum QT interval minus minimum QT interval) 
was proposed as an index of the spatial dispersion of ventricular recovery. 
QTd measurement is an attempt by which we can distinguish homogenous 
myocardium from inhomogenous myocardium. In other words increased QT 
dispersion reflects the disparity of ventricular recovery times. Hence QT 
dispersion provides a cheap, simple and non invasive method to measure 
underlying dispersion of ventricular excitability 
(6)
. 
 
There is an absolute need for the development of affordable 
parameters to detect and identify the risk of development of ventricular 
arrhythmias associated with acute myocardial infarction and to prevent 
sudden cardiac deaths associated with it 
(4, 5)
.  
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AIMS AND OBJECTIVES 
 
1. To study QT dispersion in acute myocardial infarction and its 
comparison after thrombolysis between early and late reperfusion 
therapy. 
2. To compare QT dispersion between successful thrombolysis and 
failed thrombolysis.  
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REVIEW OF LITERATURE 
 
HISTORICAL REVIEW 
Coronary artery disease and myocardial infarction 
There are evidences of human sufferings from coronary artery disease 
from the time of civilizations. Ancient Egyptian, Roman, Greeks and 
Biblical literature have clear evidences
(7)
. It was Hippocrates who first said 
sudden cardiac deaths could be due to disease of the heart. 
 
In 1768, classical angina pectoris was described by Heberden. 
In1809, imbalance between myocardial oxygen supply and need was 
postulated by Burns. Hammer was the first one to demonstrate antemortem 
coronary thrombosis in 1878. 
 
In early 19 century Osler said heart continues to function even after 
infarction. Later studies by Obrastzow and Straschesko in 1912 showed 
AMI is not always fatal and is usually due to thrombosis and can be 
diagnosed before death 
(8)
. In 1945 Radner visualised coronary arteries and 
in 1948 anticoagulant therapy was used. The use of enzymes to diagnose 
myocardial infarction was first demonstrated by Ladue. In 1962, Mason 
performed first coronary angiography. Later Effler and Favoloro started 
doing endarterectomy and grafting. 
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It was only recently that the full understanding of the development of 
cascade of events leading to the complete coronary artery occlusion by 
fibrin platelet thrombus postulated and the reperfusion in the form of 
fibrinolysis or PCI started. 
 
Historical aspects of ECG and QT dispersion 
Augustus recorded first electrocardiogram by using capillary 
Electrometer
(9)
. Later William Einthoven developed string galvanometer and 
was awarded noble prize in 1924 for his work on electrocardiogram and 
published reports done with it. Later Mackenzie and Lewis proposed the 
advantages of electrocardiograph in diagnosing arrhythmias
(10).
 In 1928 
Parkinson and Bedford
(11)
 showed the evolutionary electrocardiographic 
changes after infarction. 
 
In 1957, Jerwell and Lange Neilson described sudden cardiac death 
associated with long QT interval 
(12)
. In 1963, Romono and Ward described 
a similar condition with ventricular arrhythmias 
(13)
.  Zabel et al 
(14)
 
hypothesized that QT dispersion is an indirect measure of heterogenecity of 
ventricular repolarisation. My et al 
(15) 
said QT interval dispersion is a 
marker of susceptibility of ventricular arrhythmias. 
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Bazett showed QT interval is influenced by heart rate and it is related 
to the ventricular systole. This has led to the development of formula which 
corrects QT interval for heart rate, corrected QT interval 
(16)
. 
 
Acute myocardial infarction 
Acute myocardial infarction is a leading killer disease globally and is 
one of the most common diagnoses in hospitalised patients in both 
developed and developing countries. In United States 650,000 new AMI and 
450,000 recurrent AMI occur each year 
(17)
. It is an indirect indicator of 
society’s development. Acute MI is caused when there is sudden and total 
occlusion of epicardial coronary artery leading to myocardial necrosis. 
Myocardial infarction occurs when ischemia exceeds the critical threshold 
for a considerable duration, far beyond myocardial cellular repair 
mechanisms designed to maintain normal function. 
 
This critical ischemia results when there is an interruption of supply 
of oxygen and nutrients due to the occlusion of artery by thrombus over an 
ulcerated, fissured atherosclerotic plaque 
(18)
. This sudden cessation of blood 
flow to coronary artery leads to cessation of aerobic metabolism, depletion 
of creatinine phosphate and onset of anaerobic glycolysis sets in. 
Irreversible injury starts occurring after 20 minutes in the absence of 
significant collaterals 
(19)
. 
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Hibernating myocardium is a late consequence of ischemia after re-
establishing normal coronary arterial flow, which protects the heart from 
subsequent ischemic episodes resulting in chronic contractile dysfunction. 
Myocardial stunning is a regional depression in myocardial contractility 
after resolution of ischemia in the absence of tissue necrosis. This may take 
considerable time to recover leading to reversibly dysfunctional 
myocardium occurring in the setting of ACS 
(20, 21)
. 
 
Myocardial infarction is classified based on the anatomical, regional 
and diagnostical clinical. Morphologically or anatomically it is divided into 
non-transmural and transmural types. A transmural MI is one in which the 
full thickness of the myocardial segment(s) extending from endocardium to 
epicardium through myocardium is affected. A non-transmural MI is where 
the ischemic necrosis does not involve full thickness of myocardial 
segment(s), limiting itself to the endocardium, myocardium or epicardium. 
It is the endocardial and subendocardial region that is least perfused. Earlier 
classification of AMI based on ECG as Q wave and non Q wave MI was 
based on the presence of Q waves on ECG. However the presence or 
absence of Q waves on ECG did not distinguish transmural AMI from non-
transmural AMI 
(25)
.   
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Now universal definition of myocardial infarction is stated and 
accordingly MI should be used in the setting of myocardial necrosis 
consistent clinically with symptoms of AMI. Accordingly AMI is classified 
into  
 
 Type 1 Spontaneous MI in the setting of primary coronary event (eg. 
Plaque rupture, fissuring, ulceration or dissection).  
 Type 2 MI in the setting of mismatch between supply and demand 
(anaemia,     coronary spasm, arrhythmias, hypotension)  
 Type 3 Sudden unexpected cardiac death, including cardiac arrest 
with symptoms suggestive of AMI and ECG features of new ST 
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elevation and new onset left bundle branch block or definite new 
thrombus by coronary angiography. 
 Type 4a MI associated with Percutaneous coronary intervention. 
 Type 4b MI associated with post stent thrombosis. 
 Type 5 MI associated with CABG (24).  
 
Myocardial infarction can also be classified into STEMI and 
NSTEMI based on the presence or absence of ST segment elevation 
respectively on surface 12 lead ECG, however both represent a continuum 
of the same spectrum of ACS. The management protocol also differs for 
STEMI and NSTEMI. 
 
Prevalence 
Coronary artery disease has become a leading cause of mortality 
worldwide in most industrialised nations and increasing even more in 
developing countries
 (22)
. By 2020 WHO estimates 20 million CVD deaths 
an year and by 2030 it is expected to increase to 24 million. It is estimated 
that 650,000 new cases of MI and 450,000 recurrent MI occur each year in 
United States alone. However, the mortality caused by MI also has 
improved considerably due to better management.  
 
The incidence of MI is increasing due to an aging society coupled 
with a sedentary lifestyle. 
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RISK FACTORS 
Smoking 
Tobacco consumption in any form is an important risk for the 
development of CVD for both sexes in any age and a preventable cause of 
death 
(23)
. A strong dose- response relation exists between cigarette smoking 
and CHD, the risk increases two to three fold in active smokers and 
increases by 20 to 30 % and interacts with other multiple risk factors 
(26)
. 
Oxidative stress plays the central pivotal role by decreasing nitric oxide 
synthesis in endothelial cells. Other mechanisms are nicotine and 
carbonmonoxide induced direct damage to endothelial cells, reduces HDL –
C, increased platelet aggregation and fibrinogen levels, vascular reactivity 
and hypertension. 
 
Hypertension 
High B.P confers silent cardiovascular risk, many studies have clearly 
showed a strong, positive and linear relation between CVD risk with both 
systolic and diastolic blood pressure 
(27)
. Wide pulse pressure which reflects 
arterial stiffness is an independent risk factor in predicting new and 
recurrent MI 
(28)
. Isolated systolic hypertension due to stiff artery and 
hypertension is associated with metabolic syndrome. Various mechanisms 
by which hypertension has its effects are increased myocardial wall stress 
and oxygen requirement, endothelial dysfunction, endothelial permeability 
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to lipoproteins, triggering acute plaque rupture and finally but not the least 
increased oxidative stress. 
 
Diabetes mellitus 
Hyperglycemia, insulin resistance and diabetes mellitus are major 
cardiovascular risk factors. Diabetes mellitus, both type 1 and type 2 is 
independent risk factors for CVD 
(29, 30)
. Hyperglycemia produces 
accelerated atherosclerosis even before the development of frank diabetes 
mellitus. Diabetes mellitus patients have two to eight fold increase in 
cardiovascular risk which makes upto two thirds of death in such patients. 
Diabetes abolishes the protection offered in a premenopausal woman and 
equals and even doubles the CVD risk 
(32, 33)
. Diabetes in association with 
metabolic syndrome is an added CVD risk. Potential mechanisms by which 
it acts are low HDL-c, high oxidised LDL-c and small LDL, high TGL, 
increased platelet aggregability, increased hsCRP and PAI-I, enhanced 
glycoprotein oxidation leads to accelerated atherosclerosis. Tight glycemic 
control reduces the microvascular complications and exercise increases the 
insulin sensitivity thus decreases cardiovascular mortality. 
 
Dyslipidemia 
Elevated total cholesterol, LDL-c, high triglycerides and a low HDL-
c below 40 mg/dl increase the risk of myocardial infarction. Increased LDL-
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c sustains and accelerates atherosclerosis; many genetic diseases with 
elevated LDL-c have increased CVD risk and premature onset of 
atherosclerosis 
(34)
. In most studies, therapy with statins not only slows 
down but also regress the atherosclerotic lesions of coronary artery
 (35, 36)
. 
Low HDL is becoming an increasing problem in CHD due to sedentary life 
style; there are studies showing increase in HDL-c cholesterol with the use 
of nicotinic acid and a reduction of CVD risk due to the same. 
 
Gender  
Incidence and prevalence of coronary risk is increased in men when 
compared with Pre-menopausal woman. In post menopausal women the 
margin narrows. Oestrogen therapy increases the HDL-c and there by 
decreases the coronary risk.  Estrogen decreases LDL-c, total cholesterol 
and has a favourable effect on fibrinogen, homocystine, plasma viscosity 
etc. 
 
Family history  
History of premature cardiac death in a family increases the 
individual’s risk of CHD. The exact cause is multi-factorial, genetic and 
acquired habits like smoking, high fatty diet, shared environments, 
monogenic factors. Onset of CHD in a male relative at or below 55 years 
and in female relative at or below 65 years is a documented risk. The 
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predictive value becomes stronger with increase in number of relatives 
having premature coronary events 
(37, 38)
. 
 
Physical inactivity  
Physical inactivity bears its direct effect on CHD and stroke, doubles 
the risk. Physical activity has shown to bring in an improvement and even 
regression in plaque size, as demonstrated by angiogram. Moderate physical 
activity has been well documented in reducing the coronary events by 
improving myocardial oxygen requirement and electrical stability, 
increasing insulin sensitivity and decreasing its requirement, reducing 
obesity, increases HDL-c, reduces blood pressure and increasing 
fibrinolysis. 
 
Obesity 
Obesity is an independent and a major risk factor for coronary artery 
disease according to AHA 
(39)
. Obesity accelerates the rate of atherosclerosis 
and progression of coronary artery disease. It increases the risk of diabetes, 
insulin resistance, high B.P and leads to elevated level of inflammation, 
dyslipidemia, decreased level of HDL-c, increases platelet aggregability and 
LVH. 
 
Additional emerging risk factors 
These are mainly markers of inflammation and atherosclerosis 
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Fibrinogen  
Fibrinogen is a marker of atherogenesis, helps in sustaining 
atherosclerosis by increasing blood viscosity and increasing platelet 
aggregability. Higher levels of fibrinogen are seen in smokers, obese 
individual, those on OCPs and thence increase CVD 
(40, 41)
. 
 
C- reactive protein 
CRP is considered as the novel marker of inflammation, and 
increased CRP levels have well co-related with the full spectrum of CHD 
(24)
. hsCRP has come as a novel marker in assessing and monitoring CHD. 
CRP is an acute phase reactant produced in liver and seen to increase in 
diabetes, hypertension, obesity, dyslipidemia, metabolic syndrome, chronic 
inflammations and infections 
(42)
. 
 
PATHOGENESIS 
Acute myocardial infarction is due to the sudden abrupt occlusion of 
coronary artery by a thrombus complicating artery previously affected by 
atherosclerosis which results in cessation of blood flow completely. If the 
cessation of blood flow persists more than 20 minutes irreversible injury of 
the myocardium sets in. However when the occlusion is a slow process 
STEMI does not occur because of rich collaterals.  
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The development of atherosclerotic plaque starts and sustains from 
decades before the development of MI; it is said that the process of 
atherogenesis starts from the intrauterine period. The site of atherosclerosis 
usually will be at specific arterial sites such as bifurcations, branches, 
curvatures, which increases turbulence and decrease shear stress which 
make the endothelium prone to injury. In a majority of cases thrombosis 
occurs at the site where there is thinning of fibrous cap usually at the 
shoulder region of the lipid rich core plaque. Fibrous cap thinning occurs 
due to action of proteases, elastases, metalloprotienases, collagenases, 
increased smooth muscle cell death and decreased matrix production 
(43, 44)
. 
After the formation of initial platelet monolayer, many agonists like ADP, 
epinephrine, serotonin cause platelet aggregation and release of 
thromboxane A2 causes vasoconstriction. The presence of glycoprotein 
IIb/IIIa causes platelet cross linking. 
 
Myocardial cell death occurs first in the most distal area away from 
the site of occlusion usually the endocardium or subendocardial layer of 
myocardium; later if the occlusion persists cell death extends to the 
myocardium and to epicardium. If blood flow is re-established in the 
occluded coronary artery most of the affected myocardium can be salvaged. 
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The damage caused depends upon distinct factors  
1. The territory supplied by the affected vessel  
2. The duration of occlusion. 
3. Whether or not it is completely occluded.   
4. The presence of collaterals to the affected area.  5. Oxygen demand in 
the affected area.   
5. Endogenous factors that produces early lysis .   
6. The adequacy of myocardial perfusion in the infarct territory after 
flow is re-established in an occluded artery. 
 
Less commonly STEMI occurs due to hypercoagulable conditions, 
cocaine abuse, connective tissue disorders, and embolism originating from 
cardiac chambers 
(45)
. 
 
Signs and symptoms 
Myocardial infarction presents with typical clinical features, with 
sometimes symptoms varying from a simple epigastric pain to sudden 
cardiac death, particularly in diabetes, where asymptomatic MI is commonly 
seen due to autonomic neuropathy. Severity of AMI cannot be assessed 
clinically based on symptoms. Despite this varied clinical presentation of 
AMI there are some characteristic symptoms as such as -                                                     
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chest pain – crushing, squeezing, heaviness over the chest, tight band 
around the chest. 
 
 Radiation of pain to both shoulder, arm, jaws, or back 
 Shortness of breath 
 Epigastic discomfort  
 Excessive sweating or diaphoresis  
 Nausea, vomiting  
 Syncope or presyncope, palpitations 
 Altered sensorium and shock 
 
AMI can occur at any time but usually seen to cluster around early 
morning or within a few hours after awakening due to the circadian 
variations in the vascular tone. Many a times it is associated with 
precipitating factors like anxiety, emotional stress, and physical exertion or 
during hospitalisation due to various illnesses. 
 
On examination patient may be tossing over the bed in order to 
relieve the pain, cold and clammy skin, cool peripheries, tachycardia, soft 
s1, presence of s3, s4 (indicates ventricular dysfunction), transient 
midsystolic or late systolic apical systolic murmur (indicating mitral 
valvular apparatus dysfunction). About one third to half of inferior wall MI 
patients have bradycardia and hypotension due to parasympathetic 
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overactivity. Temperature may be minimally raised on the first day due to 
release of cytokines and carotids pulse may be weak owing to reduced 
stroke volume which regains over time. After some time, pericardial rub 
may be heard. 
 
In evaluating any patient with chest pain one should thoroughly 
assess the severity of complaints, aim to identify potential precipitating 
factors (accelerated hypertension) and evidence of complications like 
hypotension, mitral regurgitation, congestive cardiac failure 
(47)
.  Diagnosis 
of AMI can be suspected in a patient who has classical symptoms and has 
the risk factors for it but a definitive diagnosis is possible only after 
confirmatory tests. These tests are electrocardiography, cardiac enzyme 
study, echocardiography. 
 
Electrocardiography 
Electrocardiograph has to be taken in all patient presenting with chest 
pain who has risk factors preferably as rapidly as possible to evaluate, 
locate, and determine the prognosis in a case of ACS and to plan the 
modality of treatment 
(48)
. The 12 lead serial electrocardiogram is also taken 
to follow the changes occurring over time. New transient or persistent ST 
segment abnormalities that develop during characteristic symptoms of ACS 
suggest acute ischemia. A normal or near normal ECG has 80-90% negative 
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predictive value regardless of patients symptoms 
(49)
. A 12 lead ECG is poor 
in examining right ventricle, posterior wall for which one should take 
additional right sided leads like v3R and v4R, posterior leads like v7, v8, v9 
may improve sensitivity for diagnosing right ventricle and posterior wall 
infarction .The 12 lead ECG is used to classify patients into 3 groups – 
 
1. ST segment elevation or development of new onset bundle branch 
block (amicable for reperfusion therapy). 
2. ST depression or T wave inversion. 
3. Those with no ST T wave changes and are non diagnostic. 
 
However identification of STEMI in a pre existing LBBB is difficult and 
one should utilise Sgarbossa criteria 
(49)
 by – 
1. ST segment elevation > 1mm concordant with the QRS complex. 
2. ST segment depression >1mm in leads v1, v2 and v3. 
3. ST segment elevation >5mm discordant with the QRS complex.  
4. Additional diagnostic changes are 1. Pathologic Q wave in lead 1, 
aVL, v5, v6 2. Precordial R wave regression 3. Late notching of S 
wave in v1 to v4 4. ST segment deviation in the same direction as 
major QRS deflection 
(50)
. 
 
Leads representing their respective walls 
 Anterior wall V3 – V4 
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 Extensive anterior V2 – V5 
 Anteroseptal V1 – V3 
 Anterolateral V4 – V6, I, AVL 
 Lateral I, II, AVL 
 Inferior II, III, AVF 
 Posterior V1, V2 (Reciprocal) 
But normal ECG does not rule out acute myocardial infarction. 
 
Serum Cardiac biomarkers 
Certain proteins which are present inside myocardial cell leak out into 
peripheral circulation due to damage to the cardiac myocyte membrane. The 
rate of their appearance in the circulation depends upon their intracellular 
location, molecular weight and local lymphatic and blood flow. Rapid 
bedside assays for serum cardiac biomarkers are now available which help 
in planning management strategy particular in non diagnostic ECG. Now the 
most widely used cardiac enzymes are cardiac troponin I and troponin T, 
and MB subtype of creatinine kinase. Troponin I and T are released within 
4hrs from injury, reaches peak by 12 hrs and remain elevated upto 7 to 14 
days (trop I) 8 to 21 days (trop T) 
(51)
; CKMB starts rising by 4 to 6 hrs 
reaches peak by 12 – 24 hrs and remains elevated for 1 to 3 days. CKMB is 
more useful in the setting of recurrent infarction occurring within a week 
(52, 
53)
.  Other cardiac markers like myoglobin, high fatty binding protein (H-
29 
 
FABP), due to less specificity, are not used and needs further study
 (54)
. 
IMA- ischemia modified albumin is one other molecule, for which further 
studies regarding the specificity are awaited 
(55)
. Since these enzymes are 
elevated immediately and take sometime to appear in the circulation patients 
presenting with chest pain are treated as having AMI and then further 
evaluation done for more precise diagnosis 
(56)
. 
 
Echocardiography and Imaging  
Two dimensional echocardiography, which demonstrates wall motion 
abnormalities caused due to decreased oxygen and nutrition supply is an 
easy and non invasive procedure that can be used in an emergency room. 
One of the earliest protective mechanisms which myocardium uses is to turn 
off contraction process which is energy requiring, and this is seen in echo as 
wall motion abnormality. Although it can even detect the portion of the 
myocardium affected, differentiation between an old scar and a new 
akinesia is difficult and limits its usage. Other uses are assessment of LV 
function thence prognosis, presence of pericardial effusion; with the help of 
colour Doppler, ventricular septal defect and mitral regurgitation can also be 
assessed. 
 
There are a number of imaging modalities available like radionuclide 
imaging techniques but cumbersome technique, lack of specificity and 
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sensitivity limit their usage. Myocardial perfusion imaging using technetium 
99 sestamibi scan demonstrates cold spot in an affected area but it cannot 
differentiate between an old scar and new infarct and this limits its overall 
diagnostic utility. 
 
TREATMENT 
Treatment aims at salvaging myocardium to the maximum and 
reducing complications arising out of it .The main aim of treatment in 
emergency room is to allay the discomfort and to identify patients who are 
candidates for urgent reperfusion. 
 
Control of discomfort 
Nitrates 
Sublingual nitrate 0.4mg upto three times can be given in a patient 
with AMI in a gap of 5 minutes; if there is further recurrence of pain with an 
ongoing ischemia, intravenous nitroglycerin is considered 
(63)
. Nitroglycerin 
acts as a nitric oxide donor to the coronary artery smooth muscle and causes 
vasodilation thus increasing circulation and alleviates pain, but it is better 
avoided in those on phosphodiesterase inhibitors for a minimum period of 
not less than 24 hrs to prevent dangerous hypotension. 
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Morphine 
Morphine, an opioid analgesic, is very effective in relieving pain 
associated with STEMI. It is given intravenously in a dose of 4 to 8 mg and 
repeated in doses of 2 to 4 mg in intervals of 5 to 15 mins till the pain is 
alleviated. It reduces anxiety, sympathetic overactivity with a consequent 
reduction in heart’s metabolic demand, causes peripheral arterial and venous 
dilatation and alleviates symptoms due to pulmonary edema. Due to its 
vagotonic actions it has a tendency to cause transient bradycardia, 
hypotension which can be managed by the use of atropine. 
 
Beta blockers 
Beta blockers decrease the need for analgesics, relieve pain, reduce 
the infarct size and occurrence of life threatening arrhythmias. The 
commonly employed regimen is metoprolol 5mg intravenous injection 
every 2- 5 mins for a minimum of 3 doses; after the last dose, if there are no 
contraindications, an oral regimen of 50mg every 6 hourly is started for 48 
hrs followed by 100mg 12 hourly. However one should avoid the use of 
beta blocker in Killip class 2 or higher due to risk of developing cardiogenic 
shock 
(57, 58)
. 
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Antiplatelets  
Aspirin has shown to markedly reduce mortality and thus should be 
given as soon as possible in those without an allergy 
(59)
. Aspirin irreversibly 
inhibits cyclooxygenase -1 and thromboxane A2 in platelets and prevents 
the further occurrence of clots. It should be a non enteric coated chewable 
aspirin for a rapid and immediate benefit; dissolved soluble preparations or 
sublingual administration can also be used in a dose of 150 to 325 mg. In 
addition, the antiplatelet agent clopidogrel in the dose of 300 mg improves 
outcomes in those who are conservatively managed 
(61)
. Newer antiplatelets 
like prasugrel and ticagrelor can also be used particularly in those who 
undergo percutaneous coronary interventions. 
 
Reperfusion 
The central dogma of the treatment of AMI is reperfusion and 
currently we are in the era of reperfusion 
(62)
. The main goal of treatment for 
the patients who presents with ECG features of STEMI and new onset 
LBBB is to adequately re-establish and restore blood flow to the affected 
ischemic myocardium. This can be achieved either by use of thrombolytics, 
percutaneous coronary intervention or by bypass surgery. 
 
The patients who present with features suggestive of acute coronary 
syndrome are classified based on the presence or absence of ST segment 
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elevation and further by the presence or absence of cardiac biomarker. 
Initially all the patients receive the same treatment in the form of 
antiplatelets, sorbitrate and anticoagulation. Patients without ST segment 
elevation are presumed to suffer from non ST segment elevation myocardial 
infarction (NSTEMI) and unstable angina (UA) and are believed to have 
critical occlusion with diminished and preserved distal blood flow to the 
coronary bed. So in this scenario the main aim is to prevent progression of 
thrombus. After initial hemodynamic stabilisation they are offered coronary 
angiography and revascularisation. If the patient is hemodynamically 
unstable, they are taken up for immediate coronary angiography and 
subsequent revascularisation. Thrombolytic therapy usage is contraindicated 
in this subset of patients 
(67)
. 
 
Percutaneous coronary intervention restores blood flow completely 
and achieves TIMI 4 blood flow in upto 95% as compared to 50–60 % with 
thrombolytics; with further passage of time, the clot becomes more and 
more mature and it is less amenable for lysis with thrombolytics 
(64)
. 
 
In a subset of patients, restoration of flow within a critical limit 
prevents the development of Q waves or myocardial necrosis and is known 
as ‘’ aborting’’ the myocardial infarction. 
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COMPLICATIONS  
Complications of acute myocardial infarction are mainly divided into 
mechanical, electrical and ischemic types. Cardiogenic shock due to severe 
LV dysfunction results in high number of deaths and long term morbidity 
secondary to recurrent hospitalisation and decreased quality of life. 
 
Mechanical complications 
The common major mechanical complications include cardiogenic 
shock due to LV dysfunction, right ventricular infarction and failure, acute 
mitral regurgitation, Ventricular septal rupture, free wall rupture, 
pseudoaneurysm. 
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1. Cardiogenic shock  
It is the common complication expected in AMI, and occurs due to 
loss of contractile elements. Pump failure is now the primary cause of in 
hospital mortality 
(65)
. Individuals who have infarctions more distally may 
have preserved ventricular function due to the compensation by the un-
infarcted segments. Prior MI, old age, triple vessel disease, anterior wall 
infarction are a few risk factors 
(65,66)
 Killip and Kimball originally proposed 
a classification which helps in prognostification based on the hemodynamic 
profile of the patients, varying from no evidence of congestive cardiac 
failure to cardiogenic shock. They divided patients into four classes and in 
hospital mortality for class 1 is 0 -5% and for class 4 is 85-95%. 
 
Killips class  Characteristics  In-Hospital mortality 
Class 1  no evidence of failure  0-5 % 
Class 2  Rales, raised JVP, s3  10-20 % 
Class 3  Pulmonary edema   35-45 % 
Class 4  Cardiogenic shock   85-95 % 
 
The occurrence of cardiogenic shock is around 7% according and 
mortality is upto 80% 
(68)
. 
 
Patients with cardiogenic shock should be put on intraaortic balloon 
pump temporarily to improve coronary perfusion, cardiac output and  reduce 
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afterload. Early revascularisation procedures like percutaneous coronary 
intervention and coronary artery bypass grafting should be done for those 
who develop shock within 36 hrs following STEMI, and fibrinolytics should 
be given for patients who are unsuitable for invasive treatment if there are 
no contraindications. 
 
Other modalities of treatment which can be considered for those who 
are refractory are ventricular assist devices and extracorporeal membrane 
oxygenator which acts as a bridge therapy for those who are awaiting 
transplantation. Should we emergently revascularise occluded coronaries 
for cardiogenic shock (SHOCK) trial evaluated the effect of early 
revascularisation and showed a decrease in all cause mortality in those who 
underwent early revascularisation 
(65)
. 
 
2. Right ventricular infarction and failure 
Involvement of right ventricle is a sequelae of inferior wall 
myocardial infarction as a result of proximal right coronary occlusion 
(69)
. 
However, hemodynamically significant RV dysfunction occurs in less than 
10% in RVMI. 
 
The triad of hypotension, elevated JVP and clear lung fields in the 
setting of inferior wall MI, in addition to ECG findings of ST elevation in 
right sided leads (v3R and v4R) with RV wall hypokinesia diagnoses 
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RVMI. Moreover patients with RVMI may display Kussmaul’s sign. 
Patients with RVMI have a better outcome because right ventricle is 
relatively resistant to ischemia and dysfunction improves over a period of 24 
to 48 hours spontaneously 
(69)
. 
 
Treatment for RVMI includes volume loading with normal saline in 
order to attain a pulmonary artery wedge pressure of 18 to 20 mm of Hg. It 
is always better to monitor these patients with pulmonary artery catheter 
because overzealous use of fluids leads to RV filling and further LV 
compromise thence cardiac output. If patients are not responding to these 
measures, one should use inotropes like dobutamine (which improves 
cardiac index) and right ventricle assist devices. Reperfusion preferably 
with primary PCI improves right ventricle function and mortality 
(70)
. 
 
3. Mitral regurgitation 
Mitral regurgitation is a known complication after acute myocardial 
infarction, with mostly mild to moderate MR occurring in 13 to 45% of 
patients. However severe MR due to papillary muscle rupture is life 
threatening and accounts for 5% of mortality in AMI 
(65)
. Rupture of 
posteromedial papillary muscle is more common than anterolateral due to 
the presence of dual blood supply in the latter; the rupture may be partial or 
complete. Rupture of right ventricular papillary muscle is unlikely and when 
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it does leads to massive tricuspid regurgitation and right heart failure. Most 
patients have single vessel disease or small infarction. 
 
Clinically it manifests as pulmonary edema with new onset 
holosystolic murmur and increasing severity of heart failure develops within 
2 to 7 days after MI. 2D echocardiography demonstrates ruptured papillary 
muscle and colour Doppler can recognise acute mitral regurgitation which is 
helpful in differentiating it from ventricular septal defect. 
 
Treatment includes prompt identification and aggressive surgical 
repair & is catastrophic if treated conservatively. Available surgical 
therapies include valve repair, replacement with prosthetic valve in 
association with revascularisation & they improve mortality 
(71)
. 
 
4. Ventricular Septal rupture 
Ventricular Septal rupture occurs in 1 to 3 % and accounts for 5% of 
mortality in AMI. VSR in apical portion is seen in anterior infarction and 
those in basal inferior septum are seen in inferior wall infarction. It confers 
a very high early mortality
 (72)
. It varies in size, which determines the shunt 
and hemodynamic deterioration and chances of survival. Ventricular septal 
defect usually is associated with bundle branch blocks or complete heart 
block. 
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VSR is commonly seen between 3 to 7 days, with the development of 
holosystolic murmur better heard at the lower sternal border and invariably 
is associated with thrill and biventricular failure. Surgical treatment should 
be offered to all the patients in the form of open closures or with patch 
closure for small ruptures. Due to large infarct and associated multivessel 
disease, results are not as gratifying as mitral regurgitation 
(73, 74)
. 
 
5. Free wall rupture 
Free wall rupture occurs in 2 to 4% of patients of acute myocardial 
infarction and accounts for 12 to 15% of early AMI deaths 
(75, 76)
. Free wall 
rupture is seen more commonly in elderly, women, diabetics and 
hypertensives. It usually occurs between 1 to 4 days, involving the left 
ventricle more commonly than right ventricle and most often involves the 
lateral wall. Fibrinolysis offers no benefit but decreased incidence is seen in 
patients who undergo PCI. 
 
The clinical presentation varies from chest discomfort and 
unexplained hypotension & the outcome is usually catastrophic with 
imminent death 
 
The therapeutic goal is to perform emergency open surgical repair. 
Inotropes and intra-aortic balloon pump can be used for initial stabilisation. 
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6. Pseudoaneurysm 
Pseudoaneurysm develops due to incomplete ventricle rupture; more 
commonly a contained rupture of LV free wall occurs, where organising 
thrombus and pericardium form pseudoaneurysm which communicates with 
the ventricle via a narrow neck. Aneurysm clinically remains silent, 
gradually becomes bigger and at times can embolize thrombus into systemic 
circulation causing strokes. This condition is usually diagnosed by 
echocardiography. 
 
Spontaneous rupture of pseudoaneurysm is a possibility and therefore 
surgical treatment should be undertaken for all patients irrespective of the 
size 
(77)
. 
 
7. True ventricular aneurysm 
True ventricular aneurysms are commonly seen in patients with apical 
infarction as compared to other areas. This is a true aneurysm because it has 
all the three layers and is usually formed by a scar tissue which has a wide 
neck.  
 
The risk of developing aneurysm is greatest in those patients who are 
not reperfused in whom it is seen in upto 10 to 30 %, as compared to 5% in 
reperfused patients, and is seen particularly in anterior wall transmural MI 
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(78)
. It produces dyskinesia and paradoxical expansile wall motion 
abnormality and there- by causing mechanical disadvantage to left ventricle 
decreasing its stroke volume. Chronic aneurysm leads to heart failure, 
tachyarrythmias and systemic embolization. Death is often sudden, 
presumably due to tachyarrythmias 
(79)
. 
 
Persistent ST elevation despite reperfusion even after 6 weeks in a 
patient with acute myocardial infarction should arouse suspicion for the 
presence of chronic aneurysm although definitive diagnosis is done by 
echocardiography which demonstrates the location of aneurysmal segment. 
Complications arising out of aneurysms should be managed effectively. 
Congestive cardiac failure should be treated adequately with diuretics, ACE 
inhibitors, and digoxin. Drugs like ACE inhibitors, aldosterone antagonists, 
beta blockers should be started as soon as possible to prevent the cardiac 
remodelling. To prevent the formation of thrombus and subsequent systemic 
embolization, patients should be put on long term anticoagulants like 
warfarin and target international normalised ratio (INR) of 2 to 3 has to be 
maintained. 
 
8. Arrhythmic complications 
One of the common complications seen in the setting of acute 
myocardial infarction is the development of arrhythmias, and is seen even 
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before patient reaches the hospital. There are various causes leading to 
arrhythmias but by far the common is electrical instability which gives rise 
to re-entry circuits in the electrically inhomogenous ischemic myocardium 
(80, 81)
. Primary ventricular fibrillation is the commonest cause of sudden 
cardiac death in AMI. Premature ventricular depolarisations (PVC) is by far 
the most common arrhythmia and sometimes can come as a warning prior to 
the development of ventricular fibrillation, particularly multifocal PVCs, 
couplets and runs, PVCs with R on T phenomena. Observation and 
monitoring is good enough as prophylactic suppression of PVCs has not 
shown any proven benefit in prevention of ventricular arrhythmias and may 
be even detrimental 
(82)
. Accelerated idioventricular rhythm is also seen very 
frequently in upto 20 %, usually following successful reperfusion. However, 
its occurrence is frequent even in those who are not reperfused making it a 
poor marker for reperfusion induced arrhythmias. Sustained ventricular 
tachycardia is also fairly common both in early and late course of STEMI, 
particularly in late phase of STEMI with poor LV systolic function. 
Abolition of VT and correction of underlying precipitating factors is very 
important as progression to ventricular fibrillation is commonly seen, and if 
resistant and refractory, use of implantable anti tachycardia devices is 
mandatory. The incidence of ventricular fibrillation is approximately 2% to 
4% and is decreasing in the post reperfusion era. Secondary ventricular 
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fibrillation occurs in patients with LV failure. Amiodarone may be used to 
treat ventricular arrhythmias in the dosage of 150 mg as loading dose 
followed by 1mg/min for first 6 hrs and 0.5mg/min for next 18hrs. 
Lidocaine in the dosage of 1mg/kg for a maximum of 100 mg followed by 
1-4mg/min can be used in those refractory to amiodarone.  
 
Polymorphic ventricular tachycardia is a rare complication which can 
be treated with amiodarone and lignocaine.  
 
Patients with poor LV reserve with recurrent ventricular tachycardia 
can be treated with implantable defibrillators, particularly those who have 
ejection fraction below 30 %. 
 
Bradyarrythmias like transient sinus bradycardia, atrioventricular 
block are more common in inferior and RVMI. Sinus bradycardia seen in 
inferior wall MI is due to heightened vagal tone which can be treated using 
atropine. AV block occurs in the setting of AMI particularly in inferior and 
right ventricular infarction. Generally SupraHis blocks have narrow 
complex with stable rhythm seen usually in inferior MI as compared to infra 
His conduction disturbances which are unstable and have wide complex 
escape rhythm. 
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Treatment for higher degrees of block like mobitz type 2, trifasicular 
blocks with significant symptoms and complete AV block is transvenous 
pacing to improve hemodynamics. 
 
Supraventricular arrhythmias: Sinus tachycardia is, by far, the most 
common type and occurs due to sympathetic overactivity and anxiety. Atrial 
fibrillation is seen in 15% of patients, representing ongoing atrial ischemia, 
which portends bad prognosis; treatment depends upon the ventricular 
response. In patients with rapid ventricular rate, immediate cardioversion is 
done to prevent the further aggravation of ischemia. If ventricular response 
is moderate then beta blockers or calcium channel blockers can be 
administered. Atrial fibrillation in AMI is associated with a higher mortality 
and increased incidences of stroke 
(83, 84)
. 
 
9. Embolic complication 
The overall incidence of development of thrombus in STEMI has 
decreased over the past decades to less than 5% due to the widespread use 
of aggressive antithrombotic strategy 
(85)
 with risk of developing mural 
thrombus the highest in anterior wall MI. Early in the phase of AMI, the 
endocardial layer is inflamed and makes the surface thrombogenic while in 
chronic phase, due to presence of wall motion abnormalities, ventricular 
aneursyms and atrial fibrillation predispose to the formation of mural 
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thrombus. The risk of systemic embolisation is quite high in large mobile 
thrombus and in those associated with akinetic or dyskinetic myocardium. 
 
Treatment includes anticoagulation by intravenous heparin with a 
target aPTT of 1.5 – 2 times that of control followed by warfarin with INR 
of 2-3 for a minimum 3 to 6 months. 
 
10. Pericarditis 
Pericarditis in acute myocardial infarction is seen in upto 8 to 10 %. 
Pericarditis can be seen from as early as first day to 6 weeks, and usually 
presents with pain that is difficult to differentiate with ischemic pain but the 
radiation of pain to both the trapezius ridge is characteristic of acute 
pericarditis. Pain of pericarditis increases with deep inspiration & supine 
position and gets relieved or decreased by sitting and leaning forward. Due 
to the involvement of epicardium in a transmural myocardial infarction, 
leads to acute fibrinous pericarditis. Pericardial friction rub on auscultation 
is pathognomonic and its presence correlates with a larger infarct. 
 
Although the presence of generalised ST elevation with concavity 
upward (saddle shaped) favours the diagnosis, ECG features of evolving MI 
produces a diagnostic dilemma. 
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Aspirin in high doses 650 mg given every 4-6 hourly is the treatment 
of choice 
(87)
. 
 
Dressler’s syndrome occurs within 1 to 8 weeks after myocardial 
infarction and is also known as post myocardial infarction syndrome. The 
exact pathogenesis is not known, but an immunological process has been 
suggested. Clinically presents with fever, malaise, chest discomfort, 
leuckocytosis and elevated ESR. Aspirin is the drug of choice while steroid 
is best to be avoided within first 4 weeks post MI. 
 
11. Ischemic complications 
These include recurrent infarction, post infarct angina and infarct 
extension. 
 
Recurrent infarction can be due to reocclusion of the infarct related 
artery (IRA) or infarction occurring in a separate territory. Re occlusion of 
the infarct related artery is a complication mostly seen in thrombolysed 
patients, diabetes mellitus and prior MI and portends a poor prognosis 
(87)
. 
 Multi vessel and triple vessel coronary heart disease is very common 
among diabetic & dyslipidemic patients; so recurrent MI occurring in them 
is difficult to diagnose when it occurs in first week after an AMI. In fact, 
angiographic evidence of complicated plaque in non infarct related arteries 
is very common.    
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Post infarct angina is defined as angina occurring anytime before 30 
days post AMI. Incidence is highest among those thrombolysed as 
compared to revascularised patients. Pathogenesis is said to be due to 
coronary artery spasm, and has a very high early and late mortality. 
 
The genesis and representation of electrocadiographic representation 
The P wave  
The atrial activation is done by the sino atrial node. Time taken for 
the complete activation of the atrium is 0.099 ± 0.012 secs, producing a 
normal atrial activation of 0.11 secs. Right atrial activity begins first due to 
its close location to SA node, reflecting as proximal or ascending limb of P 
wave in the frontal plane leads and ending at the apex of  P wave with a 
duration ranging from 0.02 to 0.04 sec. Activation of the left atrium begins 
0.03 secs later than right atrial activation and constitute descending limb of 
P wave in standard lead II with a duration of left atrial activation ranging 
from 0.05 sec to 0.06 sec. Thus normal P wave is formed by composite 
deflection of right and left atrial activation. The normal morphology of P 
wave is usually best studied in standard lead II and V1 because the frontal P 
wave axis is usually directed to the positive pole of this lead. The normal P 
wave is usually in range of 0.08 sec. to 0.10 sec in duration, and maximum 
normal amplitude being less than 2.5mm. 
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PR Segment 
The PR segment begins from the end of P wave and ends with the 
onset of QRS complex. It is a flat isoelectric baseline and forms the part of 
PR interval, beginning from the onset of P wave to the onset of QRS 
complex. The normal PR interval duration ranges from 0.12 -0.2 seconds. 
 
PR interval represents temporal bridge between atrial and ventricular 
activation 
(88)
. 
 
The genesis of QRS complex 
QRS complex in ECG represents ventricular depolarisation. 
Activation of the ventricles begins in the left subendocardial region of the 
lower third of the interventricular septum, spreading transversly from left to 
right. It is opposed by a smaller activation force which occurs almost 
synchronously but fractionally later, and arises in right subendocardial 
region of the interventricular septum, spreading transversly through the 
septum from right to left. The larger left to right force dominates, 
counteracting the smaller right to left force resulting in an effective vector 
which is directed transversly from left to right through the lower third of the 
interventricular septum. This is sometimes referred to as septal force or 
septal vector. 
49 
 
 
Activation of the interventricular septum is then followed by 
activation of the free walls of both the ventricles, occurring transversely 
from subendocardial to subepicardial regions of free walls of both 
ventricles. The larger right-to-left force of the free left ventricular wall 
dominates and counteracts smaller left-to-right force of smaller right 
ventricular wall, resulting in an effective or net resultant vector which is 
directed from right to left through the free wall of left ventricle. To explain 
this in simplified terms, activation of the ventricles may be depicted as a 
small initial vector from left to right through the interventricular septum, 
followed by larger vector from right to left through the free wall of left 
ventricle.  
 
The T wave 
The T wave is normally inscribed in the same direction as the QRS 
complex. It has asymmetric limbs, the proximal limb being shallower than 
the distal limb. It has relatively blunt apex. 
 
The ST segment 
The ST segment represents ventricular repolarization, almost leaving 
the baseline immediately after its origin from the end of the QRS complex. 
Thus very little or none of it tends to be isoelectric. The ST segment usually 
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merges smoothly and imperceptibly with proximal limb of T wave, making 
it difficult to separate them. 
 
The U wave 
The U wave is a small rounded deflection which occurs immediately 
after the T wave. It is normally in the same direction as the T wave. It is 
usually best seen in leads V2 – V4. The deflection may be so small making 
accurate recognition difficult. 
 
The genesis of U wave is uncertain and remains controversial. 
 
The Q-T interval 
The Q-T interval is the interval from the starting of QRS complex to 
the end of T wave, representing the total duration of the ventricular activity 
i.e., the sum of ventricular depolarization and repolarization. The Q-T 
interval may vary in different parts of ventricles, but the Q-T interval 
measured from surface electrocardiogram represents largest Q-T interval. 
 
Measurement of Q-T interval 
Measuring Q-T interval may be difficult, because it may be difficult 
to determine the exact beginning and end of the interval. The beginning of 
QRS complex is best determined in a lead with an initial Q wave, 
commonly in order to avoid mistakes of ignoring an initial part of QRS 
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complex which may be isoelectric in a particular lead and hence not 
discernible, the Q wave being, in effect, incorporated within the PR interval. 
The precise end of T wave may, at times, also be difficult to determine; this 
is because the end of T wave may be obscured by a superimposed U wave 
or, in the case of sinus tachycardia, by the ensuing P wave. When the Q-T 
interval is measured from a lead where the U wave is prominent, the nadir 
or notch between T and U wave is taken as the end of T wave. This is not 
necessarily the true end point of the T wave but it will do for practical 
purposes. 
 
The significance of the Heart rate in relation to Q-T interval  
The Q-T interval varies with heart rate, shortening with tachycardia 
and lengthening with bradycardia. In other words Q-T interval 
proportionally changes with the R-R interval, decreasing with shortening of 
R-R interval and increases with prolongation of R-R interval. This change 
occurs due to change in refractory period of myocardium and ventricular 
repolarisation & indicates that correction of the Q-T should be done in 
relation to heart rate for purposeful analysis 
(88)
. 
 
Correction of the Q-T interval: The Q-Tc interval and its calculation  
The Q-T interval is corrected for what it would theoretically be at rate 
of 60 beat per minute 
(88)
. Q-Tc interval is the term used to denote corrected 
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QT interval. Traditionally various formulas have been formulated to correct 
Q-T interval but Bazetts formula formulated by Bazett is in vogue. 
 
Bazetts formula is 
Q-Tc = Q-T/√(R-R) 
 
The Q-T interval is calculated and the R-R interval is calculated between 
two consecutive R waves and it should be in seconds. 
 
The Q – Tc may be considered as a constant, K thus, 
Normal value for K = 0.39 Sec ± 0.04 Sec. 
Normal range thus ranges from 0.35 Sec to 0.43 Sec. 
 
Conditions associated with abnormal Q-Tc are many. Prolonged Q-Tc 
is seen in acute myocardial infarction, during sleep, hypocalcemia, acute 
myocarditis, drugs like quinidine, procainamide, tricyclic antidepressants, 
hypothermia, hypertrophic cardiomyopathy, and certain congenital long Q-T 
syndromes like Jervall–Lange Neilson syndrome, Romano-Ward syndrome 
etc. 
 
Shortened Q-Tc is seen in digitalis effect, hypercalcemia, 
hyperthermia and vagal stimulation. 
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Surface 12 lead ECG represents the longest Q-T interval and Q-T 
interval varies from lead to lead on surface ECG by upto fifty milliseconds, 
being longest in mid precordial leads V2 and V3. This variation represents 
Q-T dispersion relating itself to electrical instability and predisposing to 
ventricular arrhythmias 
(88)
. 
 
Q-T dispersion and its electrophysiological basis 
Q-T dispersion is defined as the difference between maximum and 
minimum Q-T interval in 12 lead electrocardiogram. 
 
Dispersion of repolarisation of ventricles is widely considered as a 
representation of non homogenous recovery of excitability, in other words, 
heterogeneity in ventricular repolarisation. It is commonly expressed as 
difference of the various repolarisation measured. The importance of this 
simple electrophysiological measurement was said to be associated with the 
facilitation of ventricular re-entry arrhythmias 
(89, 90, 91, 92 & 93)
. These 
experimental findings suggested dispersion of ventricular repolarisation as 
an important arrythmogenic substrate, and were later extended when 
dispersion of repolarization along the trans mural axis of the myocardium 
was shown to play a key role in the genesis of arrhythmias specifically 
associated with the acquired or congenital long QT syndrome 
(95, 96, 97)
. QT 
dispersion represents dispersion of ventricular repolarization, and therefore, 
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is a potential measure of substrates for re-entry tachycardia. Evidences 
obtained from various studies reinforce the significance of increased 
repolarization heterogeneity in the genesis of re-entry and malignant 
ventricular arrhythmias. 
 
T wave genesis and dispersion  
The basic principle behind the genesis of the T wave is very essential 
in order to understand pathophysiological meaning of QTd and its genesis 
(97)
. T wave recorded in the 12 lead surface ECG is the result of temporal 
and spatial voltage gradient within the ventricular myocardium representing 
the phase of cellular repolarisation but sometimes particularly in bundle 
branch block and premature ventricular beats it also includes phase of 
depolarisation. 
 
These voltage gradients are complex geographical representation of 
the cellular Repolarization and its dispersion in time and space. It has been 
proven time and again that the T wave from the body surface itself is a 
direct expression of dispersion of ventricular repolarization. By far, the bulk 
of the T wave represents the greater portion of ventricular repolarization 
gradients and only a small fraction of terminal portions of T wave represents 
repolarization differences in the voltage or time domain. The small amount 
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of cells which are still repolarising, minute gradients still persist but escape 
detection in some ECG leads 
(97)
. 
 
T wave is usually ignored in the standard method of QTd 
measurement. If we measure only the temporal difference the that occurs 
between the ends of the shortest and the longest QT interval between the 12  
 ECG leads; we miss out on the most important reflection of ventricular 
repolarization dispersion is the T wave proper. Hence, all the variables 
expressing either the T-wave area or the T-wave width have to be more 
tightly related to dispersion of ventricular repolarization. From this thought 
process we can hypothesize that disparities of repolarization in the voltage - 
domain, more importantly than in the time – domain (as depicted by QTd), 
can be a better appropriate index of repolarization dispersion. This idea of 
voltage domain dispersion of repolarization is experimentally supported by 
Behrens et al who showed in isolated rabbit hearts that the voltage 
differences in amplitude – normalized monophasic action potential (MAP) 
recordings closely correlated with the shape of the concurrent T wave which 
was recorded from the tissue bath chamber. Of that interestingly the T – 
wave peak seem to occur precisely at the time of the maximal difference in 
MAPs. 
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The role of early after repolarisation and genesis of QT dispersion and 
arrhythmias  
Without understanding early after depolarisation it is very difficult to 
study dispersion of ventricular repolarisation. EADs occurs more commonly 
in mid myocardial M cells and purkinje cells when they are treated with 
agents which prolong APD. EADs are nothing but the prolongation of 
repolarisation occurring in the phase 3 of action potential, which prolong 
ventricular repolarisation occurring in the myocardium, sometimes 
excessively reaching a voltage level that triggers premature depolarization. 
They occur predominantly due to reduction of net outward current which 
may be due to either an increase of inward current and/or decrease of 
outward current. In other words, EADs occurs when balance of current 
shifts inward during phase 2 or 3 of action potential. EADs precipitate 
Torsade de pointes (Tdp) arrhythmias in the setting of either congenital and 
acquired long QT syndromes by triggering mechanism or by their ability to 
sustain ectopic depolarizations within the ventricles
(98, 99)
. This is based on 
studies that EADs can be reproduced using drugs that prolong the action 
potential duration by blocking the potassium outward channel, which may 
trigger repetitive depolarization and TdP arrhythmias. 
 
By MAP catheter technology it is possible to record the recordings 
which furnishes direct insight into the pathophysiology in intact animal 
57 
 
hearts and even in patients. An example from the available literature 
induced prolonged QT intervals and episodes of (TdP). The MAP tracings 
show conspicuous prolongation of repolarisation and a prominent EAD that 
precedes the polymorphous rhythm. This action potential (AP) prolongation 
and EAD is associated with change in polarity of the T wave and the origin 
of a giant U wave. The marked prolongation of the AP also leads to 
exaggeration of dispersion of ventricular repolarization that may play a role 
in any function re entry present in sustained triggered arrhythmias. This 
possibly explains EADs developing in the selected transmural M cells can 
actually set the stage for re-entry by exaggerating transmural dispersion of 
repolarisation (TDR). It is noteworthy to remind that EAD is also a possible 
explanation in the origin of ventricular arrhythmias in cases of heart failure 
and cardiac hypertrophy. 
 
Therefore, EAD appears to play an important role in both triggering 
and sustaining serious ventricular arrhythmias. 
 
Measurement of QT dispersion 
Measurement of QT dispersion, especially its accuracy is mainly 
determined by the precision with which the QT intervals are noted in 
individual leads. However, we know that measurement of the QT interval is 
unreliable. The main problem stems predominantly because of the 
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difficulties of the exact determination of the T-wave end. Independent of 
whether the measurement is performed by a human observer or by a 
computer algorithm, the main source of error arise from specific 
morphological patterns of the T wave, merges of the T wave with the U 
wave, low amplitude of the T-wave signal, and, at fast heart rate, merges of 
the T wave with the P wave. 
 
The morphology of the T wave can influence any measurement of the 
QT interval, and frequently cited beliefs that computer algorithms are less 
affected than humans are not justified. The shape of the descending limb of 
the T wave obviously influences the determination of the T- wave end by 
any down slope tangent computer algorithm, as is any threshold algorithm 
by the amplitude of the T wave. The amplitude of the T wave very strongly 
influences the reliability of automatic 
(100, 101)
 and manual measurement. 
 
It is often very difficult, almost impossible, to separate the end of the 
T wave from the start of U wave and also to mark the end of the T wave 
with a better accuracy than that of few tens of milliseconds. In1952, 
Lepeschkin et al explained various patterns of T- and U-wave merges and 
differentiated them into 16 patterns. They also suggested methods for 
finding the end of the T wave when it is lost within the U wave. It was also 
shown that, depending on the particular pattern of T-U wave merging, either 
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the point of intersection of the tangent to the down slope steepest point and 
the isoelectric line, or the nadir between the T and the U wave is actually 
closer to the real end of the T wave. 
 
However, most of the available methods are not suitable for certain 
pattern of T-U merging, for example when U wave is augmented and/or 
when T wave is inverted or flat. This ECG pattern is usually observed in 
patients with severe hypokalemia and be mistakenly taken as a grossly 
prolonged interval that often comes before torsades de pointes tachycardia. 
 
Q-T interval after Acute Myocardial Infarction 
In early as 1953 Elk et al reported prolongation of QT interval in the 
early phase of myocardial infarction. But the relation between serial changes 
in QT interval and outcome of MI was undefined. Schwartz et al in 1975 
demonstrated risk of sudden death in patients with prolonged QT interval in 
healed MI. Later, similar association were found between a prolonged QT 
interval and high risk of sudden death even in acute myocardial infarction. 
 
Time related changes in the QT interval after acute Myocardial 
Infarction 
Doroghazi RM and Childer’s in 1978(104) first studied the sequential 
QT interval changes in AMI. They obtained Serial ECG’s after infarction 
for 14 days and the changes in the QTc was analysed retrospectively. 
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They observed prolonged QT at some point of time in first five days and by 
day six, QT interval returned to the site of peri-infarction in most cases. 
Abnormal QT Interval was observed in 37% of patients with inferior wall 
infarction and 40% of patients with anterior wall infarction. QT interval 
returned to normal at the end of 5-6 days irrespective to the degree of initial 
QT and did not prolong further thereafter. The mean QTc was found to be 
greatest on day two in the majority of the patients. They also stated the 
magnitude of QT prolongation was higher among non-transmural infarction 
as compared to transmural infarction which was statistically insignificant. 
 
Rate dependence of dispersion of repolarization  
A common point of discussion and uncertainty in dispersion of 
repolarisation and QT dispersion from ECG is how to correct QTd and other 
variables of heart rate. Earlier clinical studies of QTd used a Bazett Formula 
based algorithm for both QT dispersion and JT dispersion. Correction of 
rate of QT and JT dispersion was done under the assumption that dispersion 
of ventricular repolarization showed almost similar rate dependence as its 
duration. The adaptation of QT interval rate physiologically has been shown 
previously by others to lay within the rate adaptation characteristics of 
action potential duration. Therefore, many algorithms have been 
recommended for clinical rate correction of the QT interval. In contrast 
however, the dispersion of ventricular repolarization is shown to be rate 
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independent in an experimental study using multiple MAPs from an isolated 
rabbit heart which was paced at different heart rates. This independence of 
rate of QTd was confirmed in normal patients and also seen in patients with 
minor heart diseases. Long QT syndromes both congenital and acquired 
should not be included in this rule because this particular pathophysiological 
situation exhibits markedly increased dispersion of ventricular 
repolarization at slow heart rates. 
 
Unfortunately, before many studies of rate dependence of dispersion 
of ventricular repolarization was done and analysed, rate correction of QTd 
with reporting QTc dispersion had been widely done. QTc dispersion had 
even been advocated as an improved risk stratifier in patients. However, it is 
possible that QTd dispersion was contaminated by rate correction due to 
addition of the unnecessary heart rate variable and also the well known over 
correction of QT in patients with faster heart rates.  Heart rate an 
independent risk stratifier by itself may ironically introduce an independent 
risk marker that is then unknowingly and falsely attributed to the 
measurement of QTc dispersion 
(97)
.  
 
Therefore, rate correction of QTc dispersion and other ventricular 
dispersion variables should be avoided unless such variables are found to be 
directly influenced by heart rate. 
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QTd from surface ECG was developed as a simple noninvasive 
clinical risk marker to reflect dispersion of ventricular repolarization at the 
level of myocardium. Although its exact derivative is not yet fully 
understood or determined, QTd may depend on a composite of 
inhomogeneous repolarization forces which includes the T-wave vector and 
a changing component of local influences believed to be the main 
explanation for QTd. For many theoretical reasons, QTd may not represent 
the most useful ECG variable, actually reflecting the actual dispersion of 
ventricular repolarization. But it is very clear that dispersion of ventricular 
repolarization at the myocardial level is an important arrhythmogenic 
substrate. The future will show whether other non invasive methods in the 
making, which more directly relate to the pathophysiological substrate and 
are methodologically more robust, will be able to improve stratification of 
patients at risk for life –threatening arrhythmias. 
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MATERIALS AND METHODS 
 
This is an observational study conducted in Government Kilpauk 
medical college hospital, Department of medicine in collaboration with 
Department of Cardiology, for a period of 1 year. A total of 60 cases 
admitted with acute myocardial infarction and who are thrombolysed were 
selected for the present study from January 2011 to January 2011. 
 
Among 60 patients studied 30 cases are those who are thrombolysed 
in less than 3 hours after the onset of chest pain and rest 30 are those who 
presented late and thrombolysed later than 3 hours after onset of chest pain. 
 
Patients who fulfil inclusion and exclusion criteria were enrolled for 
the study after obtaining written informed consent. The study protocol was 
approved by the ethical committee of Govt. Kilpauk medical college 
hospital, Chennai-10 for research studies. 
 
Inclusion criteria 
Patients admitted in ICCU of Govt. Kilpauk medical college hospital 
with complaints suggestive of acute myocardial infarction and 2 lead ECG 
showing ST elevation are included in this study. The patients who are 
thrombolysed are included in the study. Age group included was everyone 
above 18 years who had acute myocardial infarction. 
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Exclusion criteria 
Medical conditions and patients who were on drugs which prolongs 
the QT interval are excluded from study like 
1. Electrolyte imbalance 
2. Patients in atrial fibrillation. 
3. Unmeasurable T waves. 
4. Patients with bundle branch block. 
5. Drugs affecting QT interval- antiarrythmics, macrolide antibiotics, 
cisapride and other prokinetic drugs. 
6. Patients with contraindications to thrombolysis. 
 
Data collection 
Detailed history was taken from the patients that includes onset of 
symptoms, past medical history and thorough physical examination and 
systemic examination was done and entered in proforma specially designed 
for this study. 
 
Blood investigations 
In all patients with myocardial infarction, routine investigation like 
complete blood count and urine examination was done. Biochemical 
parameters like random blood sugar, fasting lipid profile and cardiac 
enzymes like creatinine phosphokinase (CPK, CK-MB) was done. 
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ECG Recording: 
ECG recordings were done on admission before thrombolysis and 90 
minutes after thrombolysis, day 2 & day 5 and 6 weeks of follow up. ECG 
was recorded with an ECG recorder speed of 25mm/sec. 
 
Measurement of QT dispersion: 
QT interval was measured in all leads from the beginning of QRS 
complex to end of T wave. In the presence of U wave, QT interval was 
measured till nadir of curve between T and U waves. Each QT interval was 
corrected for the patient’s heart rate using Bazett’s formula. 
 
(QTc = QT/√ RR (sec)) (QTc is the corrected QT interval). 
 
QT dispersion on each electrocardiogram is “the difference between the 
maximal and minimal QT interval in any of the leads measured”. 
Accordingly QTc dispersion is defined as “the difference between maximal 
and minimal heart rate corrected QT interval’’. 
 
Cases were further divided into 
1. Those who presented early in less than 3 hours after AMI and 
thrombolysed early and those who are thrombolysed later than 3 
hours. 
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2. Successful and failed thrombolysed group.(failed thrombolysis based 
on clinical and ECG criteria). 
3. Ventricular Arrhythmia and No Ventricular Arrhythmia group. 
 
The obtained data’s were entered and tabulated in the Master chart 
and statistical analysis done using SPSS software. Univariate analysis was 
done with paired t- test and pearson product moment correlation co- 
efficient. P value < 0.05 was considered to be statistically significant. 
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OBSERVATIONS AND ANALYSIS 
 
TABLE 1: AGE AND SEX DISTRIBUTION OF EARLY 
REPERFUSED CASES. 
 
AGE MALE FEMALE TOTAL 
25- 30 1 0 1 
31-40 1 0 1 
41-50 6 1 7- 
51-60 5 5 10 
61-70 5 5 10 
>70 0 1 1 
 18 12 30 
 
Out of 30 cases of early thrombolysed acute myocardial infarction studied 
18 were men 
12 were women 
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CHART 1: AGE AND SEX DISTRIBUTION OF EARLY 
THROMBOLYSED CASES 
 
 
 
The average age of presentation of myocardial infarction among those 
who were thrombolysed early is 55.8 years. 
 
The maximum incidence of MI in men is seen in the age group of 41-
50 years. 
 
The maximum incidence of MI among women is seen in the age 
group of 51-60 and 61-70 years equally in the study group. 
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TABLE 2: AGE AND SEX DISTRIBUTION OF CASES IN LATE 
THROMBOLYSIS 
 
AGE MALE FEMALE TOTAL 
<30 0 0 0 
31-40 1 0 1 
41-50 3 1 4 
51-60 7 5 12 
61-70 7 6 13 
>70 0 0 0 
 18 12 30 
 
Out of 30 cases of late thrombolysed acute myocardial infarction studied  
18 were men 
12 were women 
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CHART 2: AGE AND SEX DISTRIBUTION OF CASES IN LATE 
THROMBOLYSIS 
 
 
 
The average age of presentation of myocardial infarction among those 
who were thrombolysed late is 57.9 years. 
 
The maximum incidence in men is seen in the age group of 51-60 and 
61-70 years equally. 
 
The maximum incidence among women is seen in the age group of 
61-70 years. 
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CHART 3: MEAN AGE OF PRESENTATION OF CASES IN BOTH 
EARLY AND LATE GROUP 
 
 
 
The above graph represents the mean age of presentation of acute 
myocardial infarction in early reperfused group (55.8 years) and late 
reperfused group (57.9) in our study. 
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TABLE 3: RISK FACTORS FOR MYOCARDIAL INFARCTION  
 
RISK FACTORS NUMBER OF CASES 
SMOKING 29 
HYPERTENSION 18 
DIABETES MELLITUS 25 
 
 
In our study involving 60 cases of acute myocardial infarction 
predominant risk factor for causation is smoking seen 29 cases followed by 
diabetes mellitus (25 cases) and hypertension (18 cases). All the three risk 
factors were present in 5 cases. 
 
 
 
 
 
 
 
 
 
73 
 
 
 
 
CHART 4: RISK FACTOR FOR MYOCARDIAL INFARCTION 
 
 
 
The above pie diagram represents the risk factors in percentage 
contributing for the acute myocardial infarction in our study group. 
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TABLE 4: TYPES OF MYOCARDIAL INFARCTION INCLUDED IN 
THE STUDY GROUP. 
 
   Group 
Total 
 Type of MI  Early Late 
 
ASMI 
Count 10 10 20 
% within Group 33.3% 33.3% 33.3% 
AWMI 
Count 7 5 12 
% within Group 23.3% 16.7% 20.0% 
EXT AWMI 
Count 1 0 1 
% within Group 3.3% .0% 1.7% 
Ext AWMI 
Count 0 2 2 
% within Group .0% 6.7% 3.3% 
IWMI 
Count 7 8 15 
% within Group 23.3% 26.7% 25.0% 
IWMI+PWMI 
Count 0 1 1 
% within Group .0% 3.3% 1.7% 
IWMI+PWMI+RV
MI 
Count 1 1 2 
% within Group 3.3% 3.3% 3.3% 
IWMI+RVMI 
Count 1 1 2 
% within Group 3.3% 3.3% 3.3% 
LWMI 
Count 3 2 5 
% within Group 10.0% 6.7% 8.3% 
Total 
Count 30 30 60 
% within Group 100.0% 100.0% 100.0% 
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CHART 5: TYPES OF MI INCLUDED IN THE STUDY GROUP. 
  
 
 
In the present study group, the number of various myocardial 
infarction studied in both early and late reperfused group were almost 
similar indicating no selection bias was done in recruiting the cases for the 
analysis of QT dispersion. 
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CHART 6: MEAN TIME OF PRESENTATION IN BOTH EARLY 
AND LATE GROUP 
 
 
 
The above graph represents the mean time of presentation of cases in 
both early and late group.   
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TABLE 5:  QT PAREMETERS IN BOTH STUDY GROUPS BEFORE 
AND AFTER THROMBOLYSIS. 
 
 Group N 
Mean 
QT 
Std. 
Deviation 
P-value 
Before thrombolysis  
max 
Early 30 .4727 .02377 
0.000 
Late 30 .5153 .04911 
Before thrombolysis min 
Early 30 .4220 .02524 
0.631 
Late 30 .4183 .03312 
After thrombolysis max 
Early 30 .4710 .02784 
0.000 
Late 30 .5413 .04876 
After thrombolysis min 
Early 30 .4230 .02615 
0.064 
Late 30 .4370 .03109 
 
The above observation shows the mean maximum & minimum QT 
interval between early and late groups. 
 
The correlation between Maximum QT before and after reperfusion 
in the two groups is statistically significant (p<0.05) indicating significant 
prolongation of maximum Q-T interval in late group on comparing with 
early group. 
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CHART 7: MEAN QT MAXIMUM AND QT MINIMUM IN BOTH 
STUDY GROUPS 
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TABLE 6: TABLE SHOWING MEAN QT DISPERSION BETWEEN 
EARLY AND LATE THROMBOLYSED CASES 
 
 Group N 
Mean 
QTd 
Std. 
Deviation 
P-value 
Before 
thrombolysis 
Early 30 50.33 19.025 
0.000 
Late 30 97.67 38.118 
After  
thrombolysis 
Early 30 48.33 21.509 
0.000 
Late 30 103.00 49.071 
Second day 
Early 30 112.00 40.802 
0.000 
Late 30 167.67 51.574 
Fifth day 
Early 30 44.33 19.945 
0.111 
Late 30 54.00 25.944 
Six weeks 
Early 30 48.00 18.458 
0.228 
Late 30 41.67 21.669 
 
The above observation represents the mean QTd in the early and late 
thrombolysis groups, with the QT dispersion being higher in acute 
myocardial infarction among late reperfused group than early reperfused 
group. 
 
The correlation between the QTd and time of reperfusion is 
statistically significant (p<0.05) in those taken before & after thrombolysis 
and on 2
nd
 day. 
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CHART 8: MEAN QT DISPERSION BETWEEN EARLY AND LATE 
THROMBOLYSED CASES. 
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TABLE 7: QT DISPERSION BEFORE AND AFTER 
THROMBOLYSIS IN EARLY REPERFUSION. 
 
Early 
Reperfusion 
Mean 
QTd 
N 
Std. 
Deviation 
P-value 
Before 
thrombolysis 
50.33 30 19.025 
0.000 
    
Second day after 
thrombolysis 
112.00 30 40.802 
 
 
In the above observation mean QT dispersion before thrombolysis 
(50.33ms) and  2
nd
 day after thrombolysis (112ms) is compared in the early 
thrombolysed  group and is found to be significantly increased on 2
nd
 day 
(p<0.05) . 
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CHART 9: GRAPH SHOWING QT DISPERSION BETWEEN 
BEFORE AND 2
ND
 DAY AFTER THROMBOLYSIS IN EARLY 
REPERFUSION 
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TABLE 8: QT DISPERSION BETWEEN BEFORE THROMBOLYSIS 
AND 2
ND
 DAY AFTER THROMBOLYSIS IN LATE REPERFUSION 
 
Late reperfusion Mean QTd 
Before thrombolysis 97.67 
Second day after thrombolysis 167.67 
 
In the above observation  mean QT dispersion, before thrombolysis 
(97.67ms) and 2
nd
 day after thrombolysis (167.67) in late reperfusion group 
is compared and is found to be significantly increased on 2
nd
 day (p<0.05). 
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CHART 10: GRAPH SHOWING QT DISPERSION BEFORE 
THROMBOLYSIS AND 2
ND 
DAY AFTER THROMBOLYSIS IN 
LATE REPERFUSION 
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TABLE 9: PREVALENCE OF VENTRICULAR ARRYTHMIAS IN 
EARLY AND LATE GROUP 
 
 Group 
Ventricular 
arrythmias Total 
   Yes No 
 
Early 
Count 2 28 30 
% within  6.7% 93.3% 100.0% 
Late 
Count 6 24 30 
% within  20.0% 80.0% 100.0% 
Total 
Count 8 52 60 
% within  13.3% 86.7% 100.0% 
 
 
In our study we had two cases of ventricular arrhythmias in early 
reperfused group and six cases in late reperfused group. 
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CHART 11: PREVALENCE OF ARRYTHMIAS IN EARLY AND 
LATE REPERFUSION GROUP. 
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TABLE 10:  MEAN QTd IN LATE REPERFUSION GROUP WITH 
VENTRICULAR ARRYTHMIAS. 
 
Early group 
Ventricular 
arrythmias 
N 
Mean 
QTd 
Std. 
deviation 
 
p- value 
Before 
thrombolysis 
Yes 
No 
2 
28 
85 
47.86 
7.071 
17.074 
0.005 
After 
thrombolysis 
Yes 
No 
2 
28 
100.00 
44.64 
14.142 
16.603 
0.000 
Second day 
Yes 
No 
2 
28 
160.00 
108.57 
14.142 
39.974 
0.085 
Fifth day 
Yes 
no 
2 
28 
40.00 
44.64 
000 
20.635 
0.244 
 
The above observation shows mean QT dispersion values of 
arrhythmias group and no arrhythmias group before and after thrombolysis, 
2
nd
 day and fifth day post thrombolysis.  There is a significant increase in 
QTd in those with arrhythmias compared to those without. This correlation 
is statistically significant in the ECGs taken before and after thrombolysis, 
and not in the ones taken on 2
nd
 & 5
th
 day. This indicates significant QT 
dispersion prolongation among those who had arrhythmias in the earlier 
phase of thrombolysis. 
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TABLE 11: MEAN QTd IN LATE REPERFUSION GROUP WITH 
VENTRICULAR ARRYTHMIAS. 
 
Late group 
Ventricular 
arrythmias 
N 
Mean 
QTd 
Std. 
deviation 
P-value 
Before 
thrombolysis 
yes 
no 
6 
24 
81.67 
101.67 
26.394 
39.964 
0.257 
After 
thrombolysis 
Yes 
no 
6 
24 
120.00 
98.75 
61.319 
46.092 
0.312 
Second day 
Yes 
no 
6 
24 
186.67 
162.92 
75.542 
44.671 
0.322 
Fifth day 
Yes 
no 
6 
24 
56.67 
53.33 
20.656 
27.452 
0.784 
 
The above table shows mean QT dispersion values in late reperfusion 
group in those with and without arrhythmias. There mean QT dispersion 
was more in those with arrhythmias compared to those without in the ECGs 
taken after thrombolysis but this correlation was statistically not significant 
(p>0.05) 
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TABLE 12: MEAN QTd IN SUCCESSFUL AND FAILED 
THROMBOLYSIS. 
 
 
Status of 
the 
treatment 
N 
Mean 
QTd 
Std. 
Deviation 
p-value 
Before 
thrombolysis 
success 56 73.93 38.408 
0.957 
Failure 4 75.00 41.231 
After 
thrombolysis 
success 56 75.71 44.716 
0.977 
Failure 4 75.00 77.675 
Second day 
success 56 139.82 54.689 
0.995 
Failure 4 140.00 49.666 
Fifth  day 
success 56 47.50 21.847 
0.038 
Failure 4 72.50 35.940 
 
In the above observation QT dispersion is compared between those 
with successful and failed thrombolysis, before and after treatment till 5 
days and lower QTd is seen in the recovery phase among those with 
successful thrombolysis which is statistically significant in the one taken on 
5
th
 day post thrombolysis. 
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CHART 12: MEAN QTd IN SUCCESSFUL AND FAILED 
THROMBOLYSIS 
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DISCUSSION 
 
Acute myocardial infarction in the spectrum of ischemic heart disease 
is the most common cause of death and is seen to be increasing in the 
present scenario both in rural and urban area in both developed and 
developing nations. Due to high prevalence of risk factors like smoking, 
hypertension, diabetes mellitus, alcoholism together with adverse life style 
changes it is increasing day by day. Ventricular arrhythmias occurring in the 
acute setting adds to its high mortality though preventable 
(3)
. Recognition of 
patients developing high risk arrhythmias is a challenging job in coronary 
care units especially in setting of acute myocardial infarction. Increased QT 
prolongation and vulnerability of ventricular myocardium has been well 
studied and documented in earlier studies, nevertheless there is a need to 
develop more sophisticated and sensitive measures to identify it 
(35,118,119)
. 
However there is a strong evidence for correlation between prolongation of 
QT interval and sudden cardiac death. Previous studies have proved beyond 
doubt that successful reperfusion decreases the QT dispersion and hence 
incidence of ventricular arrhythmias and mortality 
(104, 105)
. Analysing QT 
dispersion will definitely be helpful as a simple, non invasive tool in 
predicting the arrythmogenecity of the heart and aid in the treatment 
particularly in rural areas. 
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The present study evaluates QT dispersion in patients with acute 
myocardial infarction treated with early thrombolytic therapy (< 3hrs) and 
those with a delay (>3 hrs) after the onset of chest pain. 
 
QT dispersion and myocardial infarction 
In acute myocardial infarction ventricular repolarisation is 
inhomogeneous, a complex interaction exists between an ischemic 
myocardium and depolarised dying tissue affecting QT interval and thereby 
QT dispersion. 
 
In our study, mean QT dispersion ranged from 40 milliseconds to 170 
milliseconds with lower mean QT dispersion in early thrombolysed group 
than in the late thrombolysed group and the correlation was statistically 
significant which is very much in accordance with the previous studies. The 
maximum mean QT interval is high before and after thrombolysis & on the 
second day in the late group when compared to early group and is 
statistically significant (p <0.05). 
 
In our study QT dispersion was high at the time of admission before 
and after thrombolysis & on day 2, QT dispersion was highest. Thereafter, it 
was found to decrease in course of time and stabilising by 5
th
 day. The 
correlation between the QTd and time of reperfusion is statistically 
significant (p<0.05) in those taken before & after thrombolysis and on 2
nd
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day. There was no increase in the QT dispersion after 5
th
 day and not much 
of difference in the QT dispersion between 5
th
 day and 6
th
 week ECG. 
 
TABLE 11: COMPARING MEAN QT MAXIMUM AND QT 
MINIMUM IN EARLY AND LATE GROUP AT DIFFERENT TIME. 
 
Time of ECG Early reperfused group Late reperfused group 
 QT max QT min QT max QT min 
Before thrombolysis 0.4727 0.4220 0.5153 0.4163 
After thrombolysis 0.4710 0.4230 0.5143 0.4370 
2
nd
 day o.5233 0.4080 0.5930 0.4213 
5
th
 day 0.4647 0.419 0.4790 0.425 
 
Yashuhiro Endoh, Hiroshi Kasanuki et al studied Influence of early 
coronary reperfusion on QT dispersion in acute myocardial infarction. 
Similar to our study they studied in 51 patients out of which 28 were re-
canalised early and rest 23 were re-canalised late, study revealed significant 
QT dispersion reduction between acute and recovery phase. The incidence 
of PVC and arrhythmias were also reduced in the early group.  
 
In summary they opined early coronary reperfusion reduces 
electrophysiological instability by reducing QT dispersion. 
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STUDIES No. OF CASES 
EARLY 
REPERFUSION 
QTd 
LATE 
REPERFUSION 
QTd 
Yashuhiro 
Endoh, Hiroshi 
Kasanuki  et al 
 
51 cases 
 
28 cases 
38 ± 12 ms 
23 cases 
50 ± 15 ms 
Our study 60 cases 
30 cases 
43.3 ± 19  ms 
30 cases 
54 ± 25.9 ms 
 
Yet another study on QT dispersion and thrombolytic therapy in 
acute myocardial infarction by Prabhu Shankar. S et al showed benefit of 
early successful thrombolysis in decreasing QTd and ventricular 
arrhythmias. They showed reduction in QTd among early thrombolysed 
cases. 
 
Comparison study of QT dispersion between primary coronary 
angioplasty and thrombolysis by Cavusoglu Y, Gorenek B involving 42 
patients showed better reduction of QT dispersion in those who underwent 
primary coronary angioplasty compared to those who were thrombolysed, 
and higher QTd was seen among those with anterior wall MI compared to 
inferior wall MI. 
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In summary QT dispersion is higher in AMI and successful 
reperfusion either by thrombolysis or PCI reduces QT dispersion, 
ventricular inhomogenecity and occurrence of arrhythmias. 
 
In our study, ventricular arrhythmias occurred in 2 cases in early 
reperfused group and in six cases of late reperfused group. There was higher 
QT dispersion in cases with arrhythmias comparing to those without in early 
reperfused group which was also statistically significant in those taken 
before and after thrombolysis, but there was no significant QT dispersion 
prolongation in late group. A higher incidence of ventricular arrhythmias 
among late reperfused group is seen, indicating earlier successful 
thrombolysis results in decreasing the occurrence of arrhythmias. 
 
QT dispersion among successful and failed cases 
In our study there were totally 4 cases which were considered as 
treatment failure based on clinical grounds and ECG criteria i,e  with 
persistent chest pain and reduction of ST segment elevation not more than 
50% at 90
th
 minute after thrombolysis. Even though mean QT dispersion 
was higher among failed cases it was not statistically significant (p>0.05) in 
the earlier period post thrombolysis. However with recovery (i.e. on 5
th
 day 
post thrombolysis), the QTd was significantly lower in those with successful 
thrombolysis. 
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LIMITATIONS OF THE STUDY 
 
1. Sample size was small so further studies with bigger sample size has 
to be done to further verify the results. 
2. Our study has excluded AMI with bundle branch block and atrial 
fibrillation and this may have produced an underestimation of 
arrhythmias and mortality. 
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CONCLUSION 
 
1. QT dispersion was higher among those who were reperfused later 
than 3 hours than those who were reperfused earlier. 
2. Incidence of arrhythmias was high among late group than early group 
indicating early successful thrombolysis reduces occurrence of 
arrhythmias. 
3. QT dispersion was lower in those with successful thrombolysis 
during the recovery phase 
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LIST OF ABBREVIATIONS USED 
 
STEMI - ST segment elevation myocardial infarction 
AMI  - Acute myocardial infarction 
MI  - Myocardial infarction 
QTd  - QT dispersion 
PCI  - Percutaneous coronary intervention 
ACS  - Acute coronary syndrome 
ECG  - Electrocardiogram 
CABG - Coronary artery bypass graft 
NSTEMI - Non ST segment elevation myocardial infarction 
WHO  - World health organisation 
CVD  - Cerebrovascular disease 
CHD  - Coronary artery disease 
HDL-c - High density lipoprotein cholesterol 
hs CRP - High sensitivity C–reactive protein 
LDL-c - Low density lipoprotein cholesterol 
TGL  - triglycerides 
AHA  - American heart disease 
LVH  - Left ventricular hypertrophy 
ADP  - Adenosine diphosphate 
LBBB - Left bundle branch block 
UA  - Unstable angina 
TIMI  - Thrombolysis in myocardial infarction 
JVP  - Jugular venous pressure 
RVMI - Right ventricular myocardial infarction 
RVI  - Right ventricular infarction 
IABP  - Intra aortic balloon pump 
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VSR  - ventricular septal rupture 
ACE  - Angiotensin converting enzyme 
aPTT  - Activated partial thromboplastin time 
EAD  - Early after depolarisation 
Tdp  - torsades de pointes 
AP  - Action potential 
IRA  - Infarct related artery 
CPK  - Creatine phosphokinase 
MAP  - Monophasic action potential  
INR  - International normalised ratio 
VT  - Ventricular tachycardia 
PVC  - Premature ventricular complex 
H-FABP - Heart type fatty acid binding protein 
IMA  - Ischemic modified protein 
trop-t  - Troponin t  
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PROFORMA 
 
NAME: 
AGE: 
SEX: 
ADDRESS:      O.P/I.P No.: 
 
D.O.A:      D.O.D.: 
PRESENTING COMPLAINTS: 
Duration of chest pain – 
Past history –  
Drug history -   
 
SIGNS: 
GENERAL 
Built:    Pallor:  Icterus: 
Pedal oedema:  Fever:  Hydration: 
Clubbing   PR:   BP: 
 
CVS: 
RS: 
PER ABDOMEN: 
CNS: 
INVESTIGATIONS 
Blood: 
Complete haemogram - Hb,TC, DC, ESR 
Blood – Sugar urea and Serum creatinine 
Serum electrolytes - Na, K 
114 
 
Blood CPKMB 
Urine: Routine - alb, sugar, deposits. 
Imaging: 
X-ray chest P.A. 
ECG:  Rate – 
Rhythm – 
Axis – 
Abnormality in waves – 
QT max, QTmin – 
QTc max, QTc min – 
QT dispersion in milliseconds – 
 
ECG impression – before thrombolysis – 
After thrombolysis – 
2
nd
 day – 
5
th
 day – 
6
th
 week – 
 
Treatment:  
1. Whether thrombolysed or not  
2. Treatment outcome – successful/ failed 
3. Occurance of arrhythmias – yes/no. 
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EARLY REPERFUSION GROUP 
 
 
Sl.no Name Age Sex smoking SHT DM 
Previous  
MI 
Time of 
presentation 
Type of MI Thrmbolysis<3hrs 
Successful 
thrombolysis 
Failed 
thrombolysis 
Occurance of 
arrythmias 
1 Murugan 55 Male yes no yes no 2.5 AWMI yes yes no no 
2 Ellappan 62 Male yes yes no no 1.8 IWMI YES yes no no 
3 Muniammal 60 female no no yes no 2 ASMI yes yes no no 
4 Joseph 45 male no no yes no 2.3 ASMI yes yes no no 
5 Devi 52 female no yes no no 1.2 LWMI yes yes no no 
6 Anbalagan 48 male yes no no no 2.9 AWMI yes no yes no 
7 Dhanalakshmi 68 female no yes yes no 1.9 IWMI+RVMI yes yes no no 
8 Bhuvaneshwari 60 female no no no no 2.3 ASMI yes yes no no 
9 Tangappan 50 male yes no no no 2 IWMI yes yes no no 
10 Saravanan 32 Male yes no no no 2.8 AWMI yes yes no no 
11 Parthasarathy 67 male no yes no no 1.5 ASMI yes yes no no 
12 Dhanabhakiyam 72 female no yes yes no 3 EXT AWMI yes yes no no 
13 Kumaran 42 male yes no no no 2.1 AWMI yes no yes no 
14 Gandhimathi 65 female no no no no 3 ASMI yes yes no no 
15 Kodandaraman 62 male yes yes no yes 2.2 IWMI yes yes no no 
16 sheriff ahmed 56 male yes no yes no 1.6 AWMI yes yes no no 
17 Tamilselvi 67 female no no no no 2.3 IWMI yes yes no no 
18 Rajan 44 Male yes yes yes no 2 AWMI yes yes no yes 
19 Selvam 52 Male yes yes no no 2.5 ASMI yes yes no no 
20 Vishwanathan 56 male yes no no no 2.5 LWMI yes yes no no 
21 Ammakannu 66 female no no yes no 2 ASMI yes yes no no 
22 Rajakumar 27 male no no no no 1.5 IWMI yes yes no no 
23 Ibrahim 65 male yes no no no 2.9 IWMI+PWMI+RVMI yes yes no no 
24 Masilamani 60 female no no yes no 3 ASMI yes yes no no 
25 Rajendran 68 Male yes no no no 1 ASMI yes yes no no 
26 Vijayan 52 Male no yes no no 1.8 IWMI yes yes no no 
27 Sridaran 50 Male yes no yes no 1.5 ASMI yes yes no yes 
28 Meenakhi 48 female no no no no 2.5 LWMI yes yes no no 
29 Rajeshwari 57 female no no no no 2.3 IWMI yes yes no no 
30 Pachayammal 66 female no no yes no 2 AWMI yes yes no no 
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QTc INTERVAL AND QT DISPERSION VALUES OF EARLY REPERFUSION GROUP 
 
 
SL:NO 
CORRECTED QT INTERVAL=QTc (IN SECONDS) QT DISPERSION (IN MILLI SECONDS) 
BEFORE 
THROMBOLYSIS 
AFTER 
THROMBOLYSIS 
2ND DAY 5TH DAY 6TH WEEK BEFORE 
THROMBOLYSIS 
AFTER 
THROMBOLYSIS 
2ND 
DAY 
5TH 
DAY 
6TH 
WEEK 
MAX MIN MAX MIN MAX MIN MAX MIN MAX MIN 
1 0.45 0.38 0.41 0.35 0.53 0.37 0.43 0.4 0.45 0.42 70 60 160 30 30 
2 0.44 0.41 0.47 0.42 0.53 0.4 0.47 0.43 0.46 0.42 30 50 130 40 40 
3 0.48 0.43 0.45 0.4 0.47 0.38 0.43 0.36 0.47 0.41 50 50 90 70 60 
4 0.49 0.47 0.46 0.41 0.53 0.37 0.46 0.42 0.47 0.41 20 50 160 40 60 
5 0.47 0.41 0.46 0.43 0.54 0.41 0.47 0.41 0.45 0.42 60 30 130 60 30 
6 0.45 0.43 0.44 0.41 0.54 0.42 0.53 0.45 0.45 0.4 20 40 120 80 50 
7 0.47 0.43 0.49 0.43 0.45 0.36 0.49 0.41 0.47 0.42 40 60 90 80 50 
8 0.49 0.45 0.46 0.43 0.51 0.43 0.47 0.42 0.45 0.41 40 30 80 50 40 
9 0.47 0.41 0.48 0.43 0.5 0.41 0.48 0.42 0.47 0.44 60 50 90 60 30 
10 0.43 0.35 0.42 0.33 0.36 0.35 0.41 0.35 0.45 0.42 80 90 10 60 30 
11 0.51 0.45 0.48 0.45 0.53 0.46 0.44 0.4 0.49 0.43 60 30 70 40 60 
12 0.49 0.45 0.46 0.43 0.47 0.41 0.47 0.4 0.45 0.43 30 30 60 30 20 
13 0.49 0.41 0.45 0.43 0.51 0.43 0.52 0.43 0.49 0.43 80 20 80 90 60 
14 0.43 0.4 0.47 0.43 0.53 0.38 0.45 0.43 0.42 0.36 30 40 150 20 60 
15 0.47 0.44 0.49 0.46 0.54 0.41 0.47 0.41 0.47 0.39 30 30 130 60 80 
16 0.5 0.45 0.51 0.43 0.53 0.4 0.47 0.44 0.45 0.43 50 80 130 30 20 
17 0.47 0.43 0.45 0.43 0.51 0.43 0.45 0.41 0.46 0.39 40 30 80 30 70 
18 0.5 0.41 0.52 0.43 0.66 0.49 0.52 0.48 0.47 0.4 90 90 170 40 70 
19 0.53 0.45 0.48 0.45 0.55 0.41 0.46 0.41 0.45 0.38 80 30 60 50 70 
20 0.47 0.43 0.47 0.41 0.53 0.43 0.47 0.43 0.48 0.43 40 60 100 40 50 
21 0.45 0.4 0.49 0.44 0.56 0.43 0.45 0.43 0.44 0.39 50 40 130 20 50 
22 0.47 0.41 0.49 0.44 0.46 0.35 0.45 0.44 0.47 0.43 60 50 110 10 40 
23 0.49 0.45 0.48 0.42 0.54 0.42 0.47 0.42 0.47 0.45 40 60 120 50 20 
24 0.47 0.43 0.46 0.43 0.51 0.42 0.46 0.44 0.49 0.42 40 30 90 20 70 
25 0.47 0.41 0.49 0.44 0.53 0.4 0.47 0.41 0.47 0.39 60 50 130 60 80 
26 0.44 0.39 0.45 0.43 0.51 0.43 0.49 0.44 0.49 0.43 50 20 80 50 60 
27 0.5 0.42 0.55 0.44 0.64 0.49 0.45 0.41 0.46 0.44 80 110 150 40 20 
28 0.45 0.4 0.47 0.42 0.53 0.42 0.45 0.42 0.44 0.41 50 50 90 30 30 
29 0.47 0.44 0.48 0.43 0.56 0.36 0.44 0.41 0.47 0.43 30 50 200 30 40 
30 0.47 0.42 0.45 0.41 0.54 0.37 0.45 0.43 0.47 0.42 50 40 170 20 50 
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LATE REPERFUSION GROUP 
 
Sl.no Name Age Sex Smoking SHT DM 
Previous 
MI 
Time of 
presentation 
Type of MI Thrombolysed Successful Failed Arrythmias 
1 Ibrahim 57 male yes no no no 7 IWMI yes yes no no 
2 Dakshinamoorthy 66 male yes yes no no 6.2 AWMI yes yes no yes 
3 Murthy 48 male no yes yes no 5.6 AWMI yes yes no no 
4 Meenakshi 54 female no no yes no 9.4 ASMI yes yes no no 
5 Babu 38 male yes no no no 5 Ext AWMI yes yes no no 
6 Jayanthi 66 female no no yes no 10 IWMI yes yes no no 
7 Durai 52 male yes yes no yes 8.8 LWMI yes yes no no 
8 Rajammal 45 female no no no no 7.6 ASMI yes yes no yes 
9 Nagraj 67 male yes no yes no 6 IWMI+PWMI yes yes no no 
10 Saroja 69 female no no no no 8.8 IWMI yes yes no no 
11 Yashodha 63 female no no yes no 7.2 ASMI yes yes no no 
12 Kamalakannan 58 male yes no no no 8.8 ASMI yes yes no no 
13 Kantharaj 62 male yes no yes no 9.2 IWMI yes yes no no 
14 Dhanam 57 female no yes yes yes 6.3 AWMI yes no yes yes 
15 Robert 43 male yes yes no no 7.3 ASMI yes yes no no 
16 Elumalai 65 male yes no yes no 5 IWMI+RVMI yes yes no no 
17 Valli 54 female no no yes no 6.7 AWMI yes yes no no 
18 Chelldurai 62 male no yes no no 8.3 IWMI yes yes no no 
19 Somasundaram 55 male no no yes no 9.2 ASMI yes yes no yes 
20 Kuppammal 67 female no no no no 5.3 IWMI+PWMI+RVMI yes yes no no 
21 Jayakumar 47 male yes no no no 6.7 ASMI yes yes no no 
22 Gunasundari 56 female no no no no 7 IWMI yes yes no yes 
23 Appan raj 62 male yes no yes no 4.5 ASMI yes no yes no 
24 Mayilvahanan 60 male yes yes no no 6.3 Ext AWMI yes yes no no 
25 Senthamari 65 female no no yes no 7 IWMI yes yes no no 
26 Shanmugasundaram 51 male yes no no no 9.5 ASMI yes yes no no 
27 Kannan 67 male yes no yes no 5.6 AWMI yes yes no yes 
28 Dhakshayini 58 female no yes yes no 7.2 ASMI yes yes no no 
29 Malliga 63 female no yes no no 6.4 IWMI yes yes no no 
30 Jayaraman 60 male yes no no no 11 LWMI yes yes no no 
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QTc INTERVAL AND QT DISPERSION VALUES OF LATE REPERFUSION GROUP 
 
 
S:NO 
CORRECTED QT INTERVAL= QTc (IN SEONDS) QT DISPERSION (IN MILLI SECONDS) 
BEFORE 
THROMBOLYSIS 
AFTER 
THROMBOLYSIS 
2ND DAY 5TH DAY 6TH WEEK BEFORE 
THROMBOLYSIS 
AFTER 
THROMBOLYSIS 
2ND 
DAY 
5TH 
DAY 
6TH 
WEEK 
MAX MIN MAX MIN MAX MIN MAX MIN MAX MIN 
1 0.47 0.43 0.49 0.43 0.56 0.43 0.47 0.43 0.48 0.43 40 60 130 40 50 
2 0.53 0.47 0.5 0.46 0.62 0.4 0.47 0.39 0.48 0.39 60 40 220 80 90 
3 0.59 0.47 0.57 0.49 0.63 0.49 0.56 0.43 0.45 0.45 120 80 140 130 0 
4 0.42 0.38 0.57 0.44 0.66 0.5 0.45 0.39 0.46 0.42 40 100 190 60 40 
5 0.52 0.38 0.51 0.41 0.57 0.4 0.46 0.42 0.45 0.41 140 100 170 40 40 
6 0.55 0.44 0.56 0.47 0.6 0.43 0.47 0.43 0.49 0.45 110 90 170 40 40 
7 0.54 0.39 0.56 0.44 0.59 0.31 0.51 0.42 0.49 0.43 150 120 280 90 60 
8 0.56 0.45 0.63 0.47 0.49 0.45 0.51 0.45 0.47 0.43 90 160 40 60 40 
9 0.55 0.39 0.56 0.41 0.66 0.41 0.47 0.41 0.47 0.43 160 150 150 60 40 
10 0.57 0.43 0.57 0.45 0.6 0.43 0.48 0.45 0.46 0.42 140 120 170 30 40 
11 0.5 0.43 0.59 0.42 0.57 0.35 0.47 0.43 0.45 0.39 70 170 220 40 60 
12 0.42 0.35 0.47 0.43 0.56 0.43 0.45 0.41 0.47 0.4 70 40 130 40 30 
13 0.51 0.44 0.56 0.42 0.66 0.49 0.48 0.4 0.49 0.41 70 140 170 80 80 
14 0.57 0.45 0.66 0.47 0.61 0.42 0.46 0.44 0.47 0.42 120 190 190 20 50 
15 0.5 0.43 0.54 0.47 0.66 0.47 0.51 0.46 0.49 0.45 70 70 190 50 40 
16 0.51 0.43 0.57 0.43 0.63 0.41 0.45 0.43 0.47 0.42 120 130 180 20 40 
17 0.51 0.43 0.53 0.45 0.61 0.39 0.49 0.45 0.47 0.47 80 80 120 40 0 
18 0.56 0.44 0.6 0.46 0.64 0.46 0.49 0.43 0.46 0.43 120 140 180 60 30 
19 0.45 0.4 0.47 0.42 0.57 0.34 0.45 0.39 0.46 0.43 50 50 230 60 30 
20 0.48 0.39 0.5 0.42 0.52 0.4 0.45 0.36 0.46 0.41 90 80 120 90 50 
21 0.42 0.38 0.45 0.45 0.48 0.42 0.45 0.41 0.47 0.43 40 0 60 40 40 
22 0.5 0.43 0.55 0.4 0.6 0.41 0.51 0.46 0.47 0.45 70 150 190 50 20 
23 0.56 0.48 0.52 0.47 0.56 0.39 0.53 0.43 0.5 0.41 80 50 170 100 90 
24 0.52 0.42 0.56 0.48 0.65 0.56 0.47 0.43 0.45 0.41 100 80 180 70 40 
25 0.54 0.4 0.52 0.4 0.57 0.39 0.47 0.4 0.45 0.41 140 120 180 30 40 
26 0.52 0.4 0.54 0.45 0.58 0.35 0.45 0.41 0.49 0.42 120 90 230 40 70 
27 0.53 0.43 0.52 0.39 0.6 0.35 0.5 0.43 0.46 0.42 100 130 250 70 40 
28 0.58 0.45 0.56 0.45 0.6 0.46 0.49 0.45 0.48 0.46 130 110 140 40 20 
29 0.55 0.37 0.56 0.35 0.6 0.49 0.52 0.49 0.49 0.47 180 210 110 30 20 
30 0.43 0.37 0.45 0.41 0.54 0.41 0.43 0.41 0.45 0.43 60 40 130 20 20 
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